Ocular Therapeutix (OCUL) Stock
Ocular Therapeutix (OCUL) closed at $6.02 on Nov 17, 2026; its Tenet Score is 51 of 100 against 340 Healthcare peers.
21 figures withheld by our checks. Each blank figure names its reason.
Key stats
- Close
- $6.02
- Nov 17, 2026
- Market cap
- $1.3B
- share price × the latest quarter's diluted weighted-average share count (vendor)
- 52-week range
- 5.94 – 16.44
- low → high · as of close, Nov 16, 2026
- Tenet Score
- 51/100
- Mixed · 340 Healthcare peers
Industry: Drugs
Ocular Therapeutix Inc scores 51/100. Mixed. Strongest on financial health and value, quality is the soft spot versus 340 Healthcare peers.
Tenet Score · vs sector
n=340Factor grades
Price
The whole report, at a glance · every card is a live peek, click any to open the section
- ✕ Buffett Quality
- ✕ Piotroski F-Score
- ✕ Graham Defensive
- ✕ Quality Compounder
- ✕ Drawdown Context
- ✕ Reversal Evidence
13F flows & insider trades land here.
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSu…
Similar-sized companies in Drugs
The 10 companies in this industry closest in market cap, as of Nov 16, 2026.
| Company | Tenet Score | Market cap |
|---|---|---|
| Intellia Therapeutics IncNTLA | 41 | $1.4B |
| UroGen Pharma LtdURGN | 44 | $1.4B |
| AlvotechALVO | 41 | $1.4B |
| AnaptysBio IncANAB | 53 | $1.4B |
| Novavax, Inc.NVAX | 37 | $1.3B |
| Taysha Gene Therapies IncTSHA | 58 | $1.3B |
| Innoviva IncINVA | 73 | $1.3B |
| Absci CorpABSI | 39 | $1.3B |
| Mineralys Therapeutics IncMLYS | 55 | $1.3B |
| Mannkind CorpMNKD | 29 | $1.3B |
Common questions
What sector and industry is Ocular Therapeutix in?
Ocular Therapeutix is in the Healthcare sector and the Drugs industry.
What is Ocular Therapeutix's Tenet Score?
Ocular Therapeutix's Tenet Score is 51 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.




